Does Rallies show Form 4 insider transactions for TNXP?

Yes. Rallies tracks TNXP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TNXP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TNXP. It does not provide personalized investment advice.

TNXP (Tonix Pharmaceuticals Holding Corp.) Stock Analysis - Insider Trades

Tonix Pharmaceuticals Holding Corp. (TNXP) is a publicly traded Healthcare sector company. As of May 21, 2026, TNXP trades at $14.21 with a market cap of $227.32M and a P/E ratio of -0.99. TNXP moved +5.47% today. Year to date, TNXP is -4.73%; over the trailing twelve months it is -51.51%. Its 52-week range spans $6.76 to $130.00. Analyst consensus is strong buy with an average price target of $41.33. Rallies surfaces TNXP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TNXP stock inside the company?

Recent TNXP insider activity includes LEDERMAN SETH bought 5.00K, LEDERMAN SETH bought 15.00K, Taylor Carolyn E. bought 418, Treco James bought 250, and LEDERMAN SETH bought 4.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TNXP Key Metrics

Key financial metrics for TNXP
Metric	Value
Price	$14.21
Market Cap	$227.32M
P/E Ratio	-0.99
EPS	$-14.53
Dividend Yield	0.00%
52-Week High	$130.00
52-Week Low	$6.76
Volume	393
Avg Volume	0
Revenue (TTM)	$17.56M
Net Income	$-147.39M
Gross Margin	58.56%

Recent TNXP Insider Trades

LEDERMAN SETH bought 5.00K (~$63.10K) on Mar 31, 2026.
LEDERMAN SETH bought 15.00K (~$223.35K) on Mar 18, 2026.
Taylor Carolyn E. bought 418 (~$15.06K) on Aug 21, 2025.
Treco James bought 250 (~$9.00K) on Aug 20, 2025.
LEDERMAN SETH bought 4.00K (~$86.20K) on May 15, 2025.

Latest TNXP News

Tonix to Unveil April 2021–2024 Fibromyalgia Claims Data at ISPOR 2026 — May 14, 2026
Tonix Reports 2,145 Prescribers, 5,400 Q1 Prescriptions; Secures 35M-Lives GPO Deal — May 11, 2026
Tonix’s TNX-1700 Reverses Aged Gastric Tumors, TNX-4700 Shows Potent BTLA Antagonism — Apr 23, 2026
Tonix Reports Higher Bioavailability and Two-Hour Faster tmax for TONMYA Sublingual vs Oral ER — Apr 15, 2026
Tonix’s TNX-4800 Shows 62–69 Day Half-Life, Plans 350 mg Adaptive Phase 2 in H1 2027 — Mar 31, 2026

TNXP Analyst Consensus

3 analysts cover TNXP: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $41.33.

Common questions about TNXP

Who is trading TNXP stock inside the company?: Recent TNXP insider activity includes LEDERMAN SETH bought 5.00K, LEDERMAN SETH bought 15.00K, Taylor Carolyn E. bought 418, Treco James bought 250, and LEDERMAN SETH bought 4.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TNXP?: Yes. Rallies tracks TNXP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TNXP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TNXP. It does not provide personalized investment advice.